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Responses of the Normal Human to Infusions of Plasma
from Patients with Graves' Disease *
CLAUDE D. ARNAUD,t HANS A. KNEUBUHLER,4 VIRGINIA L. SEILING,
BRUCE K. WIGHTMAN, AND NORMAN H. ENGBRING
(Fromt the Department of Medicine, Marquette University School of Medicine and Milwaukee
County General Hospital, Milwaukee, Wis.)

The cause of the hyperthyroidism of Graves' dis- role in the production of the hyperthyroidism of
ease is unknown. Ever since Loeb and Bassett this disorder remains unanswered (11).
(1) and later Siebert and Smith (2) showed that
The present investigations were designed to
hyperthyroidism could be produced in animals by study the effect of the infusion of whole plasma
injections of pituitary extracts, it has been sug- obtained from patients with Graves' disease on the
gested that excess secretion of thyrotropin (TSH) organic iodine metabolism of normal man as measis responsible for this disease in man. However, ured by changes in endogenously synthesized orthe bioassay of TSH in the blood of patients with ganically bound iodine in the blood of recipients.
Graves' disease has led to inconsistent results (3). A sensitive model for the study of thyroid-stimuUntil recently, direct experimental support of the lating substances in man was used and is described.
concept of endogenous overstimulation of the thy- The results indicate that there is a factor in the
roid gland has been lacking. The studies of plasma of some of the patients with Graves' disAdams and Purves (4-8) and of McKenzie ease studied which stimulates organic iodine me(9-11) have shown that the serum of many pa- tabolism in normal man. Furthermore, the comtients with Graves' disease contains a factor that parative patterns of response to 1) various doses
stimulates the thyroid glands of mice. This factor of bovine TSH, 2) plasma from a patient with
is different from bovine TSH in that it has a spontaneous myxedema (myxedema plasma), and
longer biologic "half-life" ( 11 ) and a delayed time 3) plasma from patients with Graves' disease
of action (7, 9) and is not inactivated by TSH anti- (Graves' plasma), who were hyperthyroid, hyposera (12). The site of production of this thyroid thyroid, and euthyroid at the time of donation, instimulator is not known, but there is negative evi- dicate that there are qualitative differences bedence which suggests that the pituitary is not its tween the effects of commercial bovine TSH and
source (11, 13). There is a close correlation be- endogenously produced TSH and those of the
tween the presence of this thyroid stimulator and thyroid-stimulating principle in Graves' plasma.
active Graves' disease, but the question of its
Methods
*Submitted for publication November 20, 1964; accepted April 8, 1965.
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01200-12, 5 MOL FR-00058-04, and 1-GS-134 and by
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Presented in part at the meeting of the Midwestern Section of the American Federation for Clinical Research,
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Service trainee in metabolism. Address requests for reprints to Dr. Claude D. Arnaud, Dept. of Biochemistry,
University of Wisconsin, Madison, Wis.
t Work done during tenure as U. S. Public Health
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Recipients. All recipients were male volunteers between the ages of 40 and 60 years. None had a personal
or family history of thyroid or hepatocellular disease nor
had they been taking any drug or iodine-containing materials. Physical examination was normal except for
mild hypertension in one, and findings were consistent
with mild chronic bronchitis in another. They were
euthyroid as evidenced by clinical evaluation by two of
us, protein-bound iodine (PBI) concentration of serum,
and 24-hour thyroidal accumulation of I'. They were
hospitalized on a metabolic ward during the entire period of study.
Donors. Case summaries of the donors are contained
in the Appendix. An outline of the pertinent manifestations of their diseases and the recipient of each plasma
are shown in Table I. Donors of normal plasma were
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RESPONSE OF NORMAL HUMAN TO GRAVES' PLASMA

young healthy males without personal or family history
of thyroid disease, and the concentrations of proteinbound iodine of these plasmas were within normal range.
Plasma. Plasma was either frozen or lyophilized immediately after it had been donated. It was studied for
its serological reaction for syphilis and its titer of antibodies to A, B, and Rh red blood cell antigens. None of
the donors had a personal or family history of liver disease nor was enlargement or tenderness of the liver detected on physical examination. Just before infusion,
plasmas were either thawed slowly or reconstituted with
sterile distilled water and studied with respect to their
ability to agglutinate the proposed recipient's red blood
cells. Judged by these criteria, all plasmas that were
infused were considered safe.
Isotope technique. The relative quantity of serum
from patients with Graves' disease that has been reported to produce maximal increases in the blood radioactivity of mice whose thyroid glands had been labeled
with I' is greater than that which could be conveniently
obtained from donors and safely infused into humans.
This made it necessary to utilize a study model in which
small changes in the endogenously synthesized organic
iodine in plasma could be precisely measured. An isotopic technique was adapted in part from that described
by Berson and Yalow (14), the sensitivity of which depends on relating the concentration of the organically
bound radioiodine in the blood to the total body radioiodine pool at the time of blood sampling.
Carrier free I' or I' (I*) as sodium iodide was given
to subjects either intravenously or orally in a single dose
of 200 Atc. Urine was collected thereafter for periods
terminated by times of blood sampling. Whenever possible,
blood was obtained every morning and at appropriate intervals after the administration of TSH or plasma. Thyroidal radioactivity was assayed with a 2-inch crystal
scintillation detector at the time of blood sampling.
Stools were collected and incinerated to ash. An automatic well-type scintillation spectrometer was employed
for assays of radioactivity in blood and excreta.
Protein-bound radioiodine (PBI*) in the plasma was
determined in duplicate as the difference between the
radioactivity assayed in 3 ml of whole plasma and that
in a 30% trichloroacetic acid extract of 3 ml of plasma
after appropriate correction for change in volume. Radioactivity in the urine was assayed on duplicate 3-ml volumes of a well-mixed sample. Three-ml weighed volumes of stool ash were counted, and the radioactivity was
related to the total weight of the specimen. Only studies in which plasma levels of radioactivity exceeded 5
times background are reported, and the counting error
of all assays never exceeded 10%.
All data were corrected for radioactive decay. Cumulative losses of radioactivity in the urine samples were
subtracted from the amount originally administered, and
a value of radioactivity retained in the body (I* RET)
coincident with blood sampling was obtained. Radioactivity excreted in the stool was found to be negligible
after the first 7 days and was disregarded in all calculations because infusion and drug studies were always per-
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formed after day 12. The plasma concentration of PBI*
was related to the size of the existing iodine pool and was
expressed as the ratio PBI* per liter to the total I* retained (PBI* L1/I* RET). Thyroidal radioactivity was
expressed in a similar manner (thyroidal I*/I* RET).
Plasma and drug administration. Neither exogenous
thyroid hormone nor antithyroid agents were given to
subjects as has been reported in animal studies (15).
In one study, 250 ml, and in all others, 500 ml of plasma
was given intravenously over a period of 1 hour. The
authors recognized the desirability of administering TSH 1
intravenously in plasma, but adverse reactions to the drug
given by this route (16) prompted intramuscular injection. TSH and plasma were administered only during the steady state period (see Results).
Experiments were originally designed so that subjects
would act as their own controls and receive in random
successive order: Graves' plasma, normal plasma, and 1 U
of TSH. This plan was altered after the results of two
normal plasma infusions were known, and it was felt that
additional studies with normal plasma would not yield
any further significant information and could not be

justified.
Data. In evaluating responses it was found that the
logarithmic transformation of the data allowed more
valid comparison of the magnitudes of the various responses. Since the pattern of response varied with the
agent administered, a valid statistical criterion of comparison could not be employed. However, within an experiment the period of response was arbitrarily considered that in which values for the PBI*/I* RET exceeded 3 times the standard deviation from the mean of
at least 4 values obtained during the control period immediately preceding drug administration (p <.01) (17).
In viewing the response curves, significance was attached only to the curve as a whole rather than to the
individual points of which it was composed. Any attempt to draw conclusions from a few points that did not
fit the general contour of the curve was felt to be too
speculative and unwarranted.

Results
Study model. The values of the ratios PBI*
L-'/I* RET and thyroidal I*/I* RET achieve an
approximately horizontal asymptote 10 to 14 days
after administration of radioiodine. There were
no exceptions to this pattern, and these results are
similar to those obtained by Berson and Yalow
(14) in euthyroid subjects. In a few potential
subjects the quantity of precipitable radioactivity
of the plasma during the steady state period was
too low for accurate assay. These subjects had
low normal values for the per cent 24-hour accumulation of radioiodine. The results of studies
1Thytropar, bovine thyrotropin, Armour Pharmaceutical Co., Kankakee, Ill.

Lo
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done with I125 were similar to those done with I13'
except that the longer half-life of I125 made it possible to study an individual subject for a longer
period of time. Steady state values of the ratio
PBI* L-1/I* RET varied little (mean standard
error of 4 determinations before administration of
a drug in all studies ± 4.0%). The sensitivity of
this system progressively diminished with time as
the levels of radioactivity declined.
Studies with TSH and myxedema plasma.
TSH was studied at three dose levels: 1.0, 5.0,
and 10.0 U. One unit elicited similar responses in
five of seven subjects. The PBI* L-1/I* RET increased rapidly from steady state levels to peak
values within the first 20 hours and then decreased
to one-half of the peak value within 24 to 36 hours
(Figure 1A). The response obtained with 10 U
of TSH (Table I, subject B.T.) was similar to
that obtained with 1 U with respect to the time of
attainment of peak values, but the amplitude and
duration of response were proportionately greater.
Five units of TSH was administered intramuscularly at the same time as the infusion of 500 ml of
normal plasma in subject S.W. (Table I). Although the pattern of response was similar to
those obtained when TSH was given without concurrent plasma infusion, the peak response was
slightly delayed. There was no change in the thyroidal 1*/I* RET after 1 U of TSH in one subject so studied, but after 10 U in subject B.T., this
index decreased slowly, reached a minimum at 36
hours, and then rose to a new steady state level
(Table I).
The response obtained following the infusion of
500 ml of myxedema plasma into subject J.S. is
illustrated in Figure 1B. It is remarkably similar
to the one shown above in Figure 1A, which was
obtained with 1 U of TSH.
Studies with Graves' plasma. Plasma was obtained from four patients with Graves' disease, one
of whom donated blood while hypothyroid after
radioiodine therapy and while euthyroid on thyroxine replacement. These plasmas were infused
into seven subjects and elicited responses that
were considered positive in five. Of the two experiments in which no response was observed, one
subject responded typically to subsequently administered TSH (L.M.) and the other (G.D.)
did not (Table I). The subject who responded to
TSH received plasma (D.J.) that had not been
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FIG. 1. RESPONSES TO THYROTROPIN (TSH) AND MYXEDEMA PLASMA. Response of subject R.J. to 1 U of bovine TSH (A) and subject J.S. to the infusion of 500
ml of plasma donated by a patient with spontaneous myxedema (B) as measured by changes in endogenously
synthesized organically bound iodine in the blood of the
recipients. TSH or plasma was administered at zero
time after stabilization of the base line. PB*I = proteinbound radioiodine; *I RET = radioactivity retained in the
body.

previously studied, but the subject who did not respond to TSH received plasma from the donor
(T.B.) whose plasma had given positive responses
(W.D. and R.J., Figure 2, A and B) 1 and 1.5
years before.
The times of the maximal responses to Graves'
plasma were delayed, and the durations of the responses were prolonged when compared with those
obtained with 1 U of TSH or myxedema plasma.
The amplitudes of responses elicited by infusions
of Graves' plasma were either equal to or slightly
less than those elicited by companion TSH responses. However, two distinct types of response

.
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FIG. 2. COMPARISON OF THE RESPONSES TO GRAVES' AND
MYXEDEMA PLASMA. Response of subject R.J. to the infusion of 250 ml of plasma donated by T.B. while the
latter was hypothyroid (A) and of subject W.D. to 500
ml of plasma donated by the same patient when he was
euthyroid (B) as measured by changes in endogenously
synthesized organically bound iodine in the recipient's
blood. (C) Figure 1B for comparison.

were observed after Graves' plasma infusions.
The results of three experiments done in different subjects are compared in Figure 2, A, B, and C.
The Graves' plasmas used in studies A and B were
obtained from the same patient (T.B.), but the
plasma used in study A was donated during a period of hypothyroidism induced by radioiodine
(PBI, 2 ug per 100 ml), and the plasma in study
B was donated after the patient had been euthyroid
(PBI, 7 ug per 100 ml) for 3 months. A clear
difference is apparent in the time of the maximal
response. The hypothyroid Graves' plasma
elicited a maximal response within the first 12
hours as did the plasma from the patient with spon-
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taneous myxedema (study C); but no response
was observed after infusion of euthyroid Graves'
plasma until 24 hours had elapsed, and peak values
were attained only after 48 hours. The infusion
of 250 ml and 500 ml of normal plasma into these
subjects (R.J. and W.D., respectively) elicited
no response (Table I).
In an attempt to confirm these observations, two
studies were done with plasma obtained from H.B.
before he was treated for severe hypothyroidism
and one with plasma from M.B., who had a mild
recrudescence of hyperthyroidism. Similar results were obtained (Table I). The hypothyroid
Graves' plasma elicited a combined (early and
delayed) response and the hyperthyroid Graves'
plasma only a delayed response. No change in
thyroidal I*/I* RET was observed after Graves'
plasma infusion in subjects R.J. and W.D.
McKenzie assay. Assay of 0.5 ml of serum
from H.B. in the McKenzie mouse assay system
for the long-acting thyroid stimulator (9) showed
an increase in blood radioactivity of 800% above
control levels at 9 hours and 200% at 3 hours.
Assays on other plasmas were not available.

Discussion
It is apparent from these studies that plasma donated by three of four patients with Graves' disease contained a factor that stimulated organic
iodine metabolism in normal man in a manner distinctly different from bovine TSH or the thyroid
stimulating material in myxedema plasma. There
is no direct evidence in the present report which
indicates that the thyroid glands of the recipients
were the sources of the increased concentrations
of organically bound iodine in the blood that were
detected following the infusion of Graves' plasma.
However, the studies of McKenzie (10) have
shown histologic changes consistent with thyroidal
overactivity in mice given repeated injections of
sera known to have long-acting stimulator activity,
and it is reasonable to assume that either direct or
indirect stimulation of the thyroid gland occurred
in the present studies.
The infusion of normal plasma probably altered
the response pattern observed after the administration of thyroid stimulating materials. As shown
in Figure 1, A and B, the peak response observed
after 500 ml of myxedema plasma is less sharp than
that obtained with intramuscular administration

Downloaded from http://www.jci.org on June 17, 2015. http://dx.doi.org/10.1172/JCI105235
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of 1 U of TSH. This suggests that dilution of
the intravascular pool of protein-bound radioactivity may have obliterated a portion of this response. The slight delay in the attainment of the
peak response observed after the concurrent administration of 5 U of TSH and 500 ml of normal
plasma (subject S.W., Table I) also suggests
this. On the other hand, the responses obtained
with either 1 U of TSH or myxedema plasma had
subsided to less than half the maximal amplitudes
within 36 hours of administration. Any response
to plasma infusion that might occur after that time
is not likely to be an artifact of volume expansion.
If the response observed after the infusion of
myxedema plasma reflects endogenously produced
TSH, its effect in man is quite similar to that of
commercial bovine TSH. Using the average total
amplitude of response obtained in five subjects as
a standard response to 1 U of bovine TSH, a gross
estimation shows that this plasma contained between 1 and 1.5 mU per ml TSH. This figure is
in good agreement with the high concentrations of
TSH that have been reported by a number of investigators to be present in the plasma of myxedematous patients (3, 18).
The two patterns of response induced by the infusion of Graves' plasma (Figure 2, A and B) that
appear to correlate with the level of circulating
thyroxine are of interest. Hyperthyroid and euthyroid Graves' plasma elicited no response during
the first 24 hours after infusion, but a rapid increase of the PBI* L-1/I* RET occurred within
4 to 8 hours after hypothyroid Graves' plasma.
If the former reflects levels of endogenous TSH
too low to measure with the technique employed,
and the latter, greater than normal concentrations
of TSH, support is given to the idea that the prolonged responses which were obtained with both
plasmas after 24 hours were separate and distinct,
and were elicited by a thyroid-stimulating substance peculiar to Graves' plasma. A critical study
designed to analyze the temporal relationships between the responses to hyperthyroid, euthyroid,
and hypothyroid Graves' plasma in the McKenzie
mouse system should be helpful in the further evaluation of these observations. The results of the
present studies, however, strongly suggest that in
Graves' disease, the TSH secreting mechanism of
the pituitary is subject to the usual negative feedback control related to blood thyroxine concen-

tration, but production of the thyroid stimulator
peculiar to Graves' disease is not. Since the responses evoked in these studies in humans are similar to those observed in animals, it is presumed
that the responsible component is the long-acting
thyroid stimulator (LATS).
Bj6rkman, Denneberg, and Hedenskog studied
the effect of the transfusion of 150 ml of blood obtained from patients with Graves' disease on the
PBI in the blood of recipients who required transfusion (19). They showed a consistent increase
in the PBI after the infusion of euthyroid or hyperthyroid Graves' blood into four of eight recipients, with maximal values attained between 30 and
40 hours. A single study in which the responses
to the intramuscular injection of 20 and 40 U of
U.S.P. TSH were compared with that obtained
with the transfusion of Graves' blood showed 1) a
similar time course of response of the PBI to TSH
and the transfusion of Graves' blood and 2) a response to Graves' blood transfusion almost as
great as the response to 20 U of TSH. In their
studies, blood samples were not obtained between
6 and 24 hours (Figure 1A). It is difficult to
evaluate the second finding of these workers; however, the most plausible explanation is that they
compared the declining portion of the responses to
large doses of TSH with those obtained with
Graves' blood.
Spontaneous Graves' disease has not been described in species other than man. The studies recorded in this paper leave little doubt that the factor in Graves' plasma which stimulates the thyroid gland of the mouse does so in the human and
in a manner qualitatively different from bovine
or human TSH. At the time that these studies
were done a method for the concentration of LATS
from plasma (20) was not generally available.
Further studies with the purified material in man,
using the technique described, should be of considerable interest.

Summary
1) A sensitive method for the study of thyroid
stimulating materials in man is described.
2) One unit of intramuscularly administered
bovine thyrotropin (TSH) induced a rapid increase in endogenously synthesized organically
bound iodine in the blood of 5 of 7 recipients.

Downloaded from http://www.jci.org on June 17, 2015. http://dx.doi.org/10.1172/JCI105235

RESPONSE OF NORMAL HUMAN TO GRAVES' PLASMA

The responses reached a peak within 20 hours and
had decreased to less than half the peak value
within 24 to 36 hours. Ten units of bovine TSH
elicited a pattern of response similar to that with
1 U, but the duration and amplitude of response
were considerably greater. Concurrent infusion
of 500 ml of normal plasma delayed by several
hours the apparent peak response to 5 U of bovine
TSH.
3) The infusion of 500 ml of plasma from a patient with spontaneous myxedema elicited a response similar to that observed with 1 U of bovine
TSH.
4) Two infusions of normal plasma into two
subjects elicited no response.
5) Plasmas obtained from four patients with
Graves' disease, with varying states of thyroid
function, were infused into seven normal recipients.
Both immediate and prolonged responses were observed with hypothyroid Graves' plasma but only a
delayed, prolonged response with euthyroid or
hyperthyroid Graves' plasma.
6) It is concluded that there is a factor in the
plasma of some patients with Graves' disease that
stimulates organic iodine metabolism in normal
man. This stimulator (presumably long-acting
thyroid stimulator) is different from bovine TSH
and the thyroid stimulating material (presumably
TSH) in plasma from a patient with spontaneous
myxedema.
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Appendix
Case summaries on plasma donors
Patient T.B., Graves' disease. A 53-year-old white
male first noted "bulging of eyes," blurred vision, and excessive tearing in 1954. In 1956 he developed increased
appetite, weight loss, increased tolerance for cold weather,
insomnia, and diplopia. Symptoms progressed causing
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him to stop work until he was treated at another hospital in 1959 with a "radioactive pill." His health improved, but symptoms recurred early in 1961. At that
time he had diffuse thyroid enlargement, exophthalmos,
fine tremor of the hands, and rapid atrial fibrillation.
Protein-bound iodine (PBI) was 15 lug per 100 ml, and
thyroidal accumulation of I' was 58% of the orally administered dose. He was treated with reserpine and 7 mc
I`. Three months later he developed signs and symptoms of mild hypothyroidism (PBI, 2.0 ,ug per 100 ml;
uptake of I' by the thyroid was 6.0%). Plasma was
obtained for study in subject R.J. Thyroxine was given
in gradually increasing amounts to 0.3 mg daily, and after the PBI remained in the range of 6.5 to 7.0 I&g per
100 ml for 3 months, plasma was drawn for study in
subject J.S. and again in 12 months for study in subject
G.D.
Patient M.B., Graves' disease. A 37-year-old white
female had had "bulging eyes" for at least 10 years. In
1959 she developed a goiter, excessive sweating, heat
intolerance, fatigue, palpitation, and nervousness, and a
subtotal thyroidectomy was performed. Exophthalmos
persisted, but she was otherwise well until October 1962,
when hyperthyroidism recurred. PBI was 8 ,tg per 100
ml, thyroidal accumulation of I' was 51%o, and this
value was suppressed only to 41% after 1 week of triiodothyronine, 25 Ag four times daily. Plasma was
drawn soon afterwards and studied in subject K.C. She
was treated with 8 mc of I', and symptoms gradually
abated.
Patient D.J., Graves' disease. A 33-year-old Negro
female suffered gradually progressive tremor of the
hands, nervousness, insomnia, palpitations, excessive
sweating, increasing appetite, and weight loss for 8
months. She had a goiter with a systolic bruit, tachycardia, pretibial myxedema, but no exophthalmos. PBI
was 21.7 ltg per 100 ml, and thyroidal accumulation of
radioiodine was 72%o. Plasma was drawn for study in
subject L.M. She was treated successfully with propylthiouracil and then subtotal thyroidectomy.
Patient H.B., Graves' disease. A 55-year-old white
male developed clubbing of fingers in 1945 at which
time he was euthyroid. He suffered rapid onset of weight
loss (50 lb), tremor, excessive sweating, and heat intolerance, but no exophthalmos, in 1952. Between 1952
and 1953 he was given 20 mc of I' in 3 divided doses.
Three months after his last dose he noted diplopia, which
was followed by exophthalmos. Between 1954 and 1955
he suffered recurrence of hyperthyroidism, which was
treated successfully with propylthiouracil, but he developed
pretibial myxedema, which was confirmed by biopsy. He
was first seen by Dr. Brian Webster in 1962 at which
time he had extensive pretibial myxedema, severe exophthalmos (O.D. 29 mm, O.S. 30 mm), moderate ophthalmoplegia, periorbital edema, clubbing of fingers and toes,
and myotonic deep tendon reflexes. Protein-bound iodine
was 1.8 lsg per 100 ml, and thyroidal accumulation of
I"' was 7.0%o. Plasma was drawn at that time for study
in subjects J.C. and P.K.
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Patient I.C., spontaneous myzedema. A 44-year-old
white female developed slowly progressive symptoms of
hypothyroidism about 12 years previously. These included cold intolerance, dry skin, lethargy, deepening of
the voice, and puffiness about the eyes. She demonstrated
the typical myxedematous features including myotonic
tendon reflexes. There was no palpable thyroid tissue.
Serum PBI was 1.5 ,ug per 100 ml, and thyroidal uptake
of radioiodine was 2.0% at 24 hours with no increases
after thyrotropin stimulation. Plasma was obtained for
study in subject J.S. before the patient was treated.
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